“We are committed to setting a new standard of excellence for people living with venous disease, and that starts with providing physicians with innovative technologies,” said Paddy O’Brien, worldwide president of Peripheral Intervention for BD. “Our acquisition of Venclose will enable us to offer a more robust portfolio of solutions to physicians who are treating the full range of venous conditions.
“The Venclose radiofrequency (RF) ablation system strategically complements our category-leading portfolio of venous disease technologies and aligns with our focus on innovations that provide transformative solutions to improve outcomes for chronic disease and enable the transition into new care settings.”
The Venclose system provides two heating length sizes (2.5cm and 10cm) in one 6Fr-sized catheter. This dynamic dual heating length catheter provides multiple operational benefits to physicians, a press release from BD states.
With 30% more heating length than the longest leading competitive RF ablation catheter, according to BD, the Venclose system can enable physicians to efficiently ablate more vein during each heating cycle and help to lower the total number of ablations required for in-vein treatment.
The company adds that the dual heating length means that physicians can ablate both long and short vein segments with the same catheter—reducing inventory management burden compared to catheters with shorter and/or static heating length sizes.
The system’s technology is also designed to help deliver a patient-centric approach to care, the press release continues. For example, its touchscreen display provides real-time procedure data to help inform physicians’ treatment decisions. Finally, the company notes that the system also provides audible tones for thermal delivery—allowing physicians to focus more of their time and attention on the patient.
Venclose was founded in 2014 to enhance the treatment of CVI through RF ablation technology. The Venclose system is currently available in a variety of healthcare settings across the USA and areas of Europe.
Terms of the transaction were not disclosed. The transaction is expected to be immaterial to BD’s fiscal 2022 financial results.